Furthermore, our results demonstrate that TRIP13 inhibition by DCZ0415 reduces tumour growth and metastasis, irrespective of p53, KRAS, BRAF, EGFR and MSI status of CRC cells, by blocking the EMT and WNT/β‐catenin pathways. Here, KRAS is linked to neoplasm.